Alcon Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Endicott
- Full Time Employees
- 25,628
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Chemin de Blandonnet 8 Geneva GE Switzerland 1214
- IPO Date
- Apr 9, 2019
- CIK
- 0001167379
- Website
- alcon.com
- Similar Companies
- Business
- Alcon Inc. (ALC) develops, manufactures and markets innovative eye care products worldwide, operating through two primary segments: Surgical, which provides a comprehensive portfolio of technologies and devices for cataract, vitreoretinal and refractive surgery including advanced technology intraocular lenses such as PanOptix and Vivity to treat cataracts, presbyopia and astigmatism, phacoemulsification systems like Centurion, femtosecond laser systems, advanced viscoelastics, surgical packs and disposable products; and Vision Care, which offers daily disposable, reusable and color-enhancing contact lenses under brands including Dailies Total1 and Air Optix, lens care solutions, and ocular health products for dry eye, allergies, redness relief and vitamins. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and its main operational base in Fort Worth where it employs around 4,500 people; it spun off from Novartis in April 2019 as a standalone public entity and conducts operations in 60 countries while serving patients in over 140 countries with products sold in more than 180 nations, including subsidiaries such as Aerie Pharmaceuticals for glaucoma therapies and WaveLight for laser eye surgery systems. Recent strategic expansions include agreements in 2025 to acquire LENSAR Inc. for approximately $356 million to integrate the ALLY Robotic Cataract Laser Treatment System and enhance femtosecond laser-assisted cataract surgery capabilities, STAAR Surgical Company for around $1.5 billion to add EVO implantable collamer lenses for myopia and astigmatism correction as a complement to laser vision procedures, a majority interest in Aurion Biotech for advanced cell therapies targeting eye diseases, and LumiThera Inc. for its photobiomodulation device treating early and intermediate dry age-related macular degeneration, with all transactions slated to close in mid-to-late 2025.
Alcon (ALC) is a Top-Ranked Momentum Stock: Should You Buy?
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
Why Alcon (ALC) is a Top Value Stock for the Long-Term
Buy 3 AI-Led Medical Devices Laggards of 1H Set to Gather Pace in 2H
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
DELL & 3 More Stocks With Strong Interest Coverage to Buy Now
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
Wall Street Analysts Predict a 27.75% Upside in Alcon (ALC): Here's What You Should Know
ALC vs. IDXX: Which Stock Is the Better Value Option?
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Here's Why Alcon (ALC) is a Strong Momentum Stock
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
Mexican Gold Announces Subscription Receipt Financing and Loan to Alcon Silver in Connection with Arrangement
Is It Too Late to Buy Alcon Inc (ALC) After 3.7% Rally? GF Value Says Undervalued
Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?